TSSK1B and scleroderma: They also demonstrated the antifibrotic efficacy of TLY012 in a mouse model of scleroderma, known as tight-skin-1 (Tsk-1) mice, as after treatment there was a decrease in hypodermal thickening, collagen deposition, and myofibroblast accumulation.